References
1. Borgsteede S, Geersing TH, Tempels-Pavlica Z. Other excipients than PEG might cause serious hypersensitivity reactions in COVID-19 vaccines. Allergy. 2021.
2. Ludger Klimek, Natalija Novak, Beatriz Cabanillas, et al. Allergenic components of the mRNA-1273 vaccine for COVID-19: possible involvement of polyethylene glycol and IgG-mediated complement activation. Authorea. January 01, 2021.
3. Lukawska, J., et al., Anaphylaxis to trometamol excipient in gadolinium-based contrast agents for clinical imaging. J Allergy Clin Immunol Pract, 2019. 7(3): p. 1086-1087.
4. Castells MC, Phillips EJ. Maintaining Safety with SARS-CoV-2 Vaccines. N Engl J Med. 2020 Dec 30. doi: 10.1056/NEJMra2035343.
5. Badiu I, Geuna M, Heffler E, Rolla G. Hypersensitivity reaction to human papillomavirus vaccine due to polysorbate 80. BMJ Case Rep. 2012 May 8;2012:bcr0220125797.
6. Stone CA Jr, Liu Y, Relling MV, Krantz MS, Pratt AL, Abreo A, Hemler JA, Phillips EJ. Immediate Hypersensitivity to Polyethylene Glycols and Polysorbates: More Common Than We Have Recognized. J Allergy Clin Immunol Pract. 2019;7:1533-1540.e8.
Figure 1. Active components and excipients listed in BNT162b2, mRNA-1273, and AZD1222 vaccines. The principles of the PEGylated-lipid nanoparticles as a delivery system for the mRNA in BNT162b2, mRNA-1273 vaccines are depicted in the upper part together to the replication-deficient adenovirus ChAdOx1 vector containing the gene of the glycoprotein spike (S) antigen of SARS-CoV-2 for the AZD1222 vaccine. Potential triggers of allergic reactions are indicated in red color in the excipient lists of each vaccine.